Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$13.46 USD
+0.05 (0.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $13.45 -0.01 (-0.07%) 4:38 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Mineralys Therapeutics, Inc.'s return on equity, or ROE, is -71.15% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that MLYS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
MLYS 13.46 +0.05(0.37%)
Will MLYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Other News for MLYS
MLYS Crosses Below Key Moving Average Level
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Insider Sell: Adam Levy Sells 73,678 Shares of Mineralys Therapeutics Inc (MLYS)
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)